Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new device aims to track the heart's pumping power in the ICU — without invasive tubes

NCT ID NCT07724262

Knowledge-focused Sponsor: Bicetre Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study tests whether the Argos system, a non-invasive monitor, can reliably measure changes in cardiac output (how much blood the heart pumps) in critically ill patients with shock. Researchers will compare its readings to those from a standard invasive device during fluid infusions or medication adjustments. If accurate, the Argos system could offer a simpler way to guide treatment in the intensive care unit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the Argos system proves reliable, it could offer a less invasive way to monitor heart function in intensive care patients.
What could go wrong
This is an early-stage observational study, not a treatment trial. The device may not match the accuracy of existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with shock defined by one sign of hypoperfusion: * systolic arterial pressure \<90mmHg * mean arterial pressure \<65mmHg * prolonged capillary refill time \>3 sec * mottling score \> 2 * urine output \< 0.1 mL/kg/h

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years old * Hospitalisation in intensive care * Haemodynamic monitoring with transpulmonary thermodilution already in place * Hemodynamic intervention deemed necessary by the clinician in charge of the patient * Administration of a fluid bolus * Change in norepinephrine dosage or performance of a vasopressor test Exclusion Criteria: * Pregnancy * Other therapeutic modification during volume expansion or the vasopressor test * Refusal to participate by relatives of the patient or the patient himself or herself * Non availability of investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bicêtre Hospital

    RECRUITING

    Le Kremlin-Bicêtre, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.